Carnosine
Anti-Aging / AntioxidantAlso known as: Beta-Alanyl-L-Histidine, L-Carnosine
Mechanism
A naturally occurring dipeptide found in muscle and brain tissue. It's one of the body's most powerful defenses against glycation — the process where sugars damage proteins and accelerate aging (forming AGEs — Advanced Glycation End-products). Also acts as an antioxidant and pH buffer in muscles. Levels decline significantly with age. Available as oral supplement, topical, or injectable.
Technical detail
Dipeptide of beta-alanine and L-histidine (beta-Ala-His). Multi-functional: (1) Anti-glycation — sacrificial nucleophile that reacts with reactive carbonyl species (methylglyoxal, glyoxal, HNE) before they can crosslink proteins, preventing AGE formation. (2) Antioxidant — histidine imidazole ring chelates redox-active Cu(II) and Fe(II), scavenges ROS (hydroxyl radical, singlet oxygen, peroxyl radicals). (3) pH buffer — pKa 6.83 (imidazole) provides buffering capacity in the physiological range, maintaining muscle pH during anaerobic exercise. (4) Anti-senescent — extends fibroblast Hayflick limit in vitro. Tissue concentrations: skeletal muscle 20-30 mM, brain 1-2 mM. Degraded by serum carnosinase (CN1) — genetic polymorphisms affect oral bioavailability.
Effects
MUSCULOSKELETAL: Buffers intramuscular pH during high-intensity exercise by neutralizing hydrogen ions (pKa 6.83), delaying onset of acidosis-induced fatigue. Increases carnosine muscle stores by 40-80% with chronic beta-alanine supplementation (RCT: Harris et al., 2006). Protects muscle proteins from glycation and oxidative crosslinking, preserving contractile function in aging muscle (animal). Maintains calcium sensitivity of contractile apparatus at low pH (in vitro). CARDIOVASCULAR: Anti-glycation activity reduces formation of advanced glycation end-products (AGEs) in vascular endothelium (RCT: small human trials showing reduced HbA1c in diabetics). Chelates zinc and copper ions that catalyze LDL oxidation (in vitro). Carnosine supplementation (2g/day) reduced blood pressure in pre-hypertensive subjects in a pilot RCT. Protects cardiomyocytes from ischemia-reperfusion injury (animal). NEUROLOGICAL: Crosses blood-brain barrier in limited amounts. Anti-excitotoxic — modulates glutamate signaling and chelates zinc released during synaptic transmission (in vitro, animal). Neuroprotective against beta-amyloid aggregation (in vitro: inhibits Aβ fibril formation). Pilot RCT in Gulf War illness showed cognitive improvement at 1.5g/day. Homocarnosine (brain-specific analog) is a GABA reservoir. ENDOCRINE: Reduces AGE-mediated damage to pancreatic beta cells, improving insulin secretion in diabetic models (animal). Lowers HbA1c by 0.3-0.6% in diabetic patients when combined with standard therapy (RCT: Baye et al., 2019 meta-analysis). IMMUNE: Modulates macrophage polarization toward M2 (anti-inflammatory) phenotype (in vitro). Reduces IL-1β, IL-6, and TNF-α production in LPS-stimulated cells (in vitro). GI: Zinc-carnosine complex (Polaprezinc) is approved in Japan for gastric ulcers. Protects gastric mucosa from NSAID-induced injury (RCT: Mahmood et al., 2007). Reduces intestinal permeability (leaky gut) by 70% in exercise-stressed athletes (RCT). SKIN: Anti-glycation activity reduces skin collagen crosslinking and yellowing associated with aging (in vitro). Topical carnosine accelerates wound closure in diabetic animal models. METABOLIC: Enhances fatty acid oxidation in muscle cells via AMPK activation (in vitro). Reduces visceral fat in high-fat-diet animal models. Improves exercise capacity and time to exhaustion when supplemented as beta-alanine (multiple RCTs, effect size d=0.18 for exercise >60s). HEPATIC: Protects hepatocytes from acetaldehyde toxicity (in vitro — relevant to alcohol-related liver damage). Reduces liver fibrosis markers in NAFLD animal models. REPRODUCTIVE: Limited data; carnosine is found in high concentrations in seminal fluid. May protect sperm from oxidative damage (in vitro). Tier 3: Practitioner protocols report subjective improvements in "brain fog" and exercise tolerance at 1-2g/day oral dosing. International data (Japan) supports zinc-carnosine for GI health with decades of post-marketing surveillance.
Practitioner Guide
DOSING TIPS: Oral carnosine has low bioavailability due to serum carnosinase (CN1) enzyme that rapidly degrades it. Two strategies: (1) Use beta-alanine 3.2-6.4g/day (the rate-limiting precursor) to increase muscle carnosine stores — this is the evidence-based athletic approach; (2) Use L-carnosine directly at 1-2g/day for systemic anti-glycation/antioxidant effects — higher doses needed due to enzymatic degradation. Some practitioners use both. RECONSTITUTION: N/A for oral; injectable carnosine is rare but used by some anti-aging practitioners at 50-200mg IM or subQ. TIMING: Beta-alanine — split doses to minimize paresthesia (tingling), take with meals. Sustained-release formulations reduce tingling. Carnosine — take on empty stomach for best absorption, 30 min before meals. SUPPLEMENT SYNERGIES: Combine with histidine (the other carnosine precursor) if using beta-alanine alone. Zinc-carnosine (Polaprezinc) is the preferred form for GI applications — 75mg twice daily with meals. Taurine may compete for the same transporter; separate by 2+ hours. Vitamin E and alpha-lipoic acid synergize for anti-glycation. CYCLING: Beta-alanine requires loading (4-6 weeks to saturate muscle stores). No cycling needed for oral carnosine. Some practitioners cycle 3 months on / 1 month off for cost reasons. STACKING: Pairs well with NAD+ precursors (NMN/NR) for comprehensive anti-aging. Complements glutathione for antioxidant coverage. Stack with CoQ10 for mitochondrial support. CONTRAINDICATION NUANCES: The tingling (paresthesia) from beta-alanine is harmless (activates MRGPRD receptors) but can alarm patients — educate them upfront. Very high-dose carnosine (>3g/day) may theoretically deplete histidine — monitor if using long-term. Patients on histamine-restricted diets should know carnosine contains histidine. STORAGE: Oral supplements — room temperature, away from moisture. Stable compound. COMPOUNDING: Some compounding pharmacies offer injectable L-carnosine 200mg/mL. Also available as nasal spray for cognitive applications (practitioner protocol, limited data). PATIENT EDUCATION: Explain that beta-alanine builds up over weeks (not acute); tingling is normal and harmless; effects on exercise performance are modest but consistent; anti-aging effects are based on anti-glycation mechanism which is well-established biochemistry.
Research Summary
TIER 1 (Gold Standard): Baye et al., 2019 — meta-analysis of carnosine supplementation in diabetes: significant reduction in fasting glucose and HbA1c (PMID: 30947749). Harris et al., 2006 — muscle carnosine loading with beta-alanine (PMID: 16868650). Saunders et al., 2017 — meta-analysis of beta-alanine and exercise performance: significant improvement for 0.5-10 min exercise bouts (PMID: 27797728). Mahmood et al., 2007 — zinc-carnosine for NSAID gastropathy RCT (PMID: 17908462). Davison et al., 2016 — RCT of carnosine supplementation on cognitive function in elderly (PMID: 27053728). TIER 2 (Strong): Boldyrev et al., 2013 — comprehensive review of carnosine physiology (PMID: 23888606). Hipkiss, 2009 — carnosine and protein carbonyl hypothesis of aging (PMID: 19135156). Examine.com entry: well-characterized for exercise performance, emerging for glycemic control. DrugBank DB00128 (beta-alanine). TIER 3 (Moderate): Japanese post-marketing data for Polaprezinc (zinc-carnosine) — decades of clinical use for gastric ulcers with excellent safety profile. Practitioner case series showing cognitive improvement in Gulf War illness (Baraniuk, 2013, small RCT, PMID: 23510943). International pharmacopoeia data from Japan supporting GI applications. Biohacking community reports improved exercise tolerance and reduced DOMS. KEY FINDINGS: (1) Beta-alanine is the most evidence-based approach for muscle carnosine loading and exercise performance. (2) Anti-glycation effects are compelling for diabetes and aging. (3) Zinc-carnosine is the standout GI application. (4) Oral carnosine has bioavailability challenges due to carnosinase. GAPS: Optimal dosing for anti-aging (separate from exercise). Long-term safety of high-dose supplementation. Whether carnosinase inhibitors could improve oral bioavailability. Direct head-to-head trials of carnosine vs. beta-alanine for non-exercise outcomes. ACTIVE TRIALS: Multiple ongoing trials for diabetes, cognitive decline, and exercise performance on ClinicalTrials.gov.